Hai Wu
Owner @ Aquila Alpha
About
Specialties: Preclinical and clinical monoclonal antibody therapeutics development, in USA and China.
United States
Palo Alto
Biotechnology
hybridoma, Antibodies, Monoclonal Antibodies, Biochemistry, Genetics, Clinical Development, humanization, recombinant antibody
Experience

Owner
Aquila Alpha

President of R&D and Global Business Development
Shanghai, China
Oversee overall R&D activities, focusing on ADC and multi specific antibodies including T cell engagers to deliver innovative bio-therapeutics to global patient populations. Leverage Mabwell’s rich and diverse pipelines for out-licensing opportunities.

CEO
Menlo Park, CA USA
Developed research and corporate strategies for both TopAlliance and its parent company Shanghai Junshi (上海君实生物). Built a pipeline of over a dozen antibody programs. Facilitated IPOs of Shanghai Junshi in both Hong Kong Stock Exchange in 2018 and Shanghai Stock Exchange in 2020.

Chief Scientific Officer
Menlo Park
Founding member of TopAlliance Biosciences (USA) which became a full subsidiary of Shanghai Junshi Biosciences in 2013. Built and led teams in US and China in developing novel antibody therapeutics against a variety of disease targets. Oversaw development of Toripalimab (anti-PD1) from early discovery into clinical phase.

Scientist
Amgen
Hybridoma generation
Hai Wu's Contact Information
Phone
Find the Right Leads
Find Verified Contact Data
What LeadContact does well
Find verified emails, phone numbers, and decision-makers with 98% accuracy.
Find Leads
Find the right people by company, role, industry, location, and more.
925M+ professional profiles

Find Emails
Access verified email addresses for your target contacts.
657M+ emails

Find Phone Numbers
Get cross-validated phone data from multiple top sources.
239M+ phone numbers

More Accurate. Lower Cost.
Find contact data in 1 tool with 98% accuracy
LeadContact integrates leading enrichment tools to deliver more accurate contact data—without paying for each one.
Great conversations start with the right contact.
It’s time to find yours.






